NCT07040917尚未招募1 期
A Study to Evaluate the Safety and Efficacy of CAR-T Cells in Subjects With Autoimmune Diseases
Chinese PLA General Hospital1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2025年9月30日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Dose Limiting Toxicity
研究概览
简要总结
The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in Subjects with autoimmune diseases.
详细描述
This is a single center, one-arm, open label study aiming to evaluate the safety and efficacy of CAR-T cells therapy in subjects with autoimmune diseases.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, between 18 and 65 years old;
- •Diagnosed with Autoimmune Diseases, such as Systemic Lupus Erythematosus, Systemic Sclerosis, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sjögren's Syndrome, Antiphospholipid Syndrome, Immune Thrombocytopenia, Pemphigus；
- •Good organ functions;
- •Subjects must understand and personally, voluntarily sign and date an informed consent.
排除标准
- •Had or has active malignancy;
- •Patients who have previously received CD19-targeted drugs, or CAR-T therapy, or any other gene therapy products;
- •Combined with other autoimmune disease that needs systemic treatment or therapy;
- •Pregnant or lactating women;
- •Has other factors that deemed not suitable by investigator.
研究组 & 干预措施
CAR-T treatment
Experimental
干预措施: CAR-T cell (Drug)
结局指标
主要结局
Dose Limiting Toxicity
时间窗: 0~28 day after treatment
Frequency of adverse events, serious adverse events
时间窗: within 24 months after treatment
次要结局
未报告次要终点
研究者
Jian Zhu
Clinical Professor
Chinese PLA General Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
A Study of CAR-T Cells in Subjects with Autoimmune DiseasesAutoimmune DiseasesNCT06762119Zhejiang University6
尚未招募
不适用
A Study of CAR-T Cells in Subjects With Systemic Lupus ErythematosusNCT06900764Wuhan Union Hospital, China24
Unknown
1 期
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and LymphomaAcute Lymphocytic LeukemiaB-cell Prolymphocytic LeukemiaDiffuse Large Cell LymphomaChronic Lymphocytic LeukemiaFollicular LymphomaMantle Cell LymphomaNCT02819583PersonGen BioTherapeutics (Suzhou) Co., Ltd.10
Unknown
1 期
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and LymphomaAcute Lymphocytic LeukemiaB-cell Prolymphocytic LeukemiaChronic Lymphocytic LeukemiaDiffuse Large Cell LymphomaFollicular LymphomaMantle Cell LymphomaNCT02851589PersonGen BioTherapeutics (Suzhou) Co., Ltd.10
招募中
不适用
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological MalignanciesMultiple MyelomaLymphomaAcute Lymphoblastic LeukemiaNCT05618041Hebei Senlang Biotechnology Inc., Ltd.50